These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Turkish validation of the overactive bladder symptom score (OABSS) and evaluation of mirabegron treatment response. Culha MG; Degirmentepe RB; Ozbir S; Cakir SS; Homma Y Int Urogynecol J; 2019 Dec; 30(12):2121-2126. PubMed ID: 31332467 [TBL] [Abstract][Full Text] [Related]
5. Clinical preferences and treatment attitudes among urologists, gynecologists, and geriatricians: An independent online questionnaire survey for comparison of treatment choices in the management of overactive bladder. Onur R; Bayrak Ö; Coşkun B; Tahra A; Ocakoglu G; Buyuran G; Mega E; Gungor Ugurlucan F; Ozturk GB Neurourol Urodyn; 2022 Nov; 41(8):1914-1923. PubMed ID: 36116064 [TBL] [Abstract][Full Text] [Related]
6. Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder. Blais AS; Nadeau G; Moore K; Genois L; Bolduc S Eur Urol; 2016 Jul; 70(1):9-13. PubMed ID: 26876327 [TBL] [Abstract][Full Text] [Related]
7. A Prospective, non-intErventional Registry Study of PatiEnts initiating a Course of drug Therapy for overactIVE bladder (PERSPECTIVE): Rationale, design, and methodology. Rovner ES; Carlson KV; Deal AS; Nair KV; Oakkar EE; Park J; Gemmen E; Kristy RM; Gooch KL; Schermer CR Contemp Clin Trials; 2018 Jul; 70():83-87. PubMed ID: 29777865 [TBL] [Abstract][Full Text] [Related]
8. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q). Margolis MK; Fox KM; Cerulli A; Ariely R; Kahler KH; Coyne KS Neurourol Urodyn; 2009; 28(5):416-22. PubMed ID: 19030182 [TBL] [Abstract][Full Text] [Related]
9. Combination Pharmacotherapy for Treatment of Overactive Bladder (OAB). El-Zawahry A Curr Urol Rep; 2019 May; 20(6):33. PubMed ID: 31098731 [TBL] [Abstract][Full Text] [Related]
12. Pelvic floor muscle training for overactive bladder symptoms - A prospective study. Fitz F; Sartori M; Girão MJ; Castro R Rev Assoc Med Bras (1992); 2017 Dec; 63(12):1032-1038. PubMed ID: 29489983 [TBL] [Abstract][Full Text] [Related]
13. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update. Athanasopoulos A; Chapple C; Fowler C; Gratzke C; Kaplan S; Stief C; Tubaro A Eur Urol; 2011 Jul; 60(1):94-105. PubMed ID: 21497434 [TBL] [Abstract][Full Text] [Related]
14. [Current state of diagnostics and treatment of overactive bladder in the Czech Republic - five years ago and today]. Krhut J; Martan A; Zachoval R; Tvrdík J; Hanus T Ceska Gynekol; 2012 Jun; 77(3):205-10. PubMed ID: 22779719 [TBL] [Abstract][Full Text] [Related]
15. A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments. Bunniran S; Davis C; Kristy R; Ng D; Schermer CR; Uribe C; Suehs BT Neurourol Urodyn; 2018 Jan; 37(1):177-185. PubMed ID: 28370541 [TBL] [Abstract][Full Text] [Related]
16. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms. Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995 [TBL] [Abstract][Full Text] [Related]
17. Contemporary management of overactive bladder. Smith AL; Wein AJ Postgrad Med; 2012 Jan; 124(1):104-16. PubMed ID: 22314120 [TBL] [Abstract][Full Text] [Related]
18. The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment. Chou EC; Hung MJ; Yen TW; Chuang YC; Meng E; Huang ST; Kuo HC J Formos Med Assoc; 2014 Aug; 113(8):506-12. PubMed ID: 25037757 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis. Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858 [TBL] [Abstract][Full Text] [Related]
20. Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment? Kobayashi M; Nukui A; Kamai T Low Urin Tract Symptoms; 2018 May; 10(2):158-166. PubMed ID: 28009939 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]